Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...